Sandusky, OH, Oct. 18, 2021 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) earlier today announced the launch of its first CBD nutraceutical product,
RelaxRX CBD
, a sleep aid.
The company plans to launch its second CBD nutraceutical product later this week, On Thursday, October 21
st
, 2021.
PAOG is on track to realize its first revenue this year, starting in Q4 2021, since the company acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). PAOG is developing both
pharmaceutical
and nutraceutical treatments base on this intellectual property.
PAOG has confirmed shipping its first and second CBD nutraceutical product to its distribution partner, North American Cannabis Holdings, Inc. (OTC Pink: USMJ). The product will soon be for sale online at
www.USMJ.com
.
PAOG expects revenue to grow rapidly following its first and second CBD nutraceutical product launches as the company has follow on products lined up to follow these products adding to overall sales potential.
Learn more about USMJ’s ecommerce site at
www.usmj.com
.
Learn more about PAOG at
www.paogroupinc.com
.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
(888) 979-2675
[email protected]
